Histrelin (Vantas)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: LH-RH agonist. Histrelin acetate inhibits gonadotropin secretion by desensitizing responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in testicular steroidogenesis.[1][2][3]
Route: subcutaneous
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

History of changes in FDA indication

  • 10/12/2004: Initial FDA approval "in the palliative treatment of advanced prostate cancer."

Patient drug information

References

  1. 1.0 1.1 1.2 Histrelin (Vantas) package insert
  2. Histrelin (Vantas) package insert (locally hosted backup)
  3. Vantas implant manufacturer's website